Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00321399 · ClinicalTrials.gov registry record
Study of Perfusion and Anatomy's Role in Coronary Artery (CAD)
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 3,019
- Enrollment target
NCT00321399: Completed study, sponsored by Brigham and Women's Hospital.
NCT00321399 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 3,019 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00321399 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 3,019 participants
- Enrollment target
Study Summary
Three main clinical outcomes will be assessed: 1. Post-test resource utilization as assessed by referral rate to catheterization within 90-days of the index study; 2. Incremental prognostic value and risk stratification for predicting cardiac death and myocardial infarction; 3. Cost-effectiveness To this end, SPARC is organized with two distinct specific objectives with important differences in patient population and endpoints. Specific Aim 1: To evaluate the impact of stress perfusion imaging with SPECT or PET, CT Angiography, and hybrid PET-CT on post-test resource utilization. The primary endpoint of specific aim 1 is to compare the impact of combined myocardial perfusion-coronary anatomy data to that of perfusion only \[stress SPECT, stress cardiac PET (without CTA)\] and anatomy only (CTA alone) on post-test resource utilization, as measured by referral to cardiac catheterization within 90 days of index noninvasive testing, in patients without CAD. Secondary endpoints: 1. to compare the diagnostic accuracy for detection of epicardial CAD of stress PET and hybrid PET-CT, stress SPECT, and CTA, as defined by coronary angiography; 2. to compare the referral rate to revascularization within 90 days of cardiac catheterization. Specific Aim 2: To compare the incremental prognostic value and risk stratification of stress perfusion imaging with SPECT or PET, CT coronary angiography, and combined perfusion-anatomy imaging approaches. The primary endpoint of specific aim 2 is to compare the incremental value of stress perfusion only (stress PET and stress SPECT), coronary anatomy only (CTA data), and combined perfusion-anatomy studies (PET+CTA and SPECT+CTA) over clinical, historical and stress test data for the prediction of cardiac death and nonfatal myocardial infarction. Secondary endpoints: 1. to compare the incremental value of these noninvasive imaging approaches over clinical, historical and stress test data for the prediction of a composite endpoint in
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,019 participants |
| Start Date | 2006-06 |
| Est. Completion | 2014-07 |
What the finished NCT00321399 record still lists
NCT00321399 is an observational study that tracks outcomes without assigning an intervention. Its 3,019 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00321399 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00321399 about?
NCT00321399 is a clinical study titled "Study of Perfusion and Anatomy's Role in Coronary Artery (CAD)". Three main clinical outcomes will be assessed: 1. Post-test resource utilization as assessed by referral rate to catheterization within 90-days of the index study; 2. Incremental prognostic value and risk stratification for predicting cardiac death and myocardial infarction; 3. Cost-effectiveness ...
What is the current status of trial NCT00321399?
This trial is currently completed. The enrollment target is 3,019 participants. The study started on 2006-06. Estimated completion is 2014-07.
Who is sponsoring clinical trial NCT00321399?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia